SILVAPHL

Silva Pharmaceuticals Limited · Pharmaceuticals and Chemicals · Cat B

0/100

High risk

৳15.6

DSE Hexagon

A mixed profile with no standout strength, held back by little dividend.

Six lenses, each scored 0–100 from the analysis. Integrity is DSE-specific — it reads how organic the price action is (high = clean, low = concentrated-operator risk). Descriptive only, not a recommendation.

Risks & rewards

Risks (3)

⚠ Earnings trending down
⚠ Dividend sustainability at risk
⚠ Financial health deteriorating

Rewards (0)

No notable positives flagged.

Score breakdown

Price history & performance

52-week high৳16.0

52-week low৳8.00

From 52w high-2.5%

Beta1.28

7D +0.0%

1M +23.8%

3M +32.2%

6M +66.0%

1Y +59.2%

YTD +64.2%

Shareholder returns vs DSEX

SILVAPHL-1.3%

DSEX+2.4%

SILVAPHL underperformed the DSEX since Jul 8, 2026 — that's when we started tracking the index, so this window will get longer over time.

Volatility

Annualized volatility38.2%

Daily VaR (95%)-3.28%

Max drawdown (5y)-70.8%

Correlation to market0.56

Typical volatility for a DSE stock. Descriptive only — past volatility is not a forecast.

Technical read

RSI (14)68.8

MACDbullish

Bollingerinside bands (+1.4σ)

Price cycle (Wyckoff)

Health trenddeteriorating

Flow pressureaccumulation

Valuation

Fair value ()

Upside—

Dividend yield+0.60%

Fundamental verdictAT-RISK

Confidence—

Ownership

Institutional holding22.52%

Foreign holding0.01%

Free float32.26%

Sponsor, institutional, foreign and public holdings from the latest disclosed shareholding pattern. Descriptive only.

Share structure

Authorized capital৳1,500mn

Paid-up capital৳1,365mn

Face value৳10

Market lot1

Outstanding shares136,500,000

Last AGM30-12-2025

Fiscal year end30-Jun

Reserve & surplus (ex-OCI)৳748mn

Other comprehensive income৳0mn

Financials

Recent P/E ratio

DateCurrent P/ETrailing P/E

Jul 14, 2026 — —

Jul 13, 2026 — —

Jul 12, 2026 — —

Jul 9, 2026 — —

Jul 8, 2026 — —

Jul 7, 2026 — —

Based on the latest un-audited financial statements. Descriptive only.

Dividend history

20241%

20231%

20223%

20215%

20205%

20196%

Earnings & NAV

YearEPSNAVDividend

2025 -0.97 15.48 0%

2024 -0.47 16.53 1%

2023 0.24 17.1 1%

2022 0.75 17.03 3%

Quarterly EPS — FY2026

Q1-0.26

Q2-0.26

Half-year-0.52

Q3-0.2

Nine-month-0.72

From disclosed annual reports and dividend declarations. Descriptive only, not a forecast.

Levels

Resistance

৳15.7

৳16.2

৳16.8

৳17.6

Support

৳15.3

৳14.6

৳14.1

৳13.5

Historical bounce zones

Aug 20, 2025: ৳11.3→৳13.3 +18%

Sep 1, 2025: ৳12→৳14.4 +20%

Nov 16, 2025: ৳7.6→৳10.2 +34%

Dec 21, 2025: ৳9→৳10.9 +21%

Mar 9, 2026: ৳8.8→৳12.9 +47%

Apr 28, 2026: ৳9.9→৳13.9 +40%

Jun 8, 2026: ৳12.5→৳14.5 +16%

Jun 23, 2026: ৳12.8→৳15.6 +22%

Sector peers

Other Pharmaceuticals and Chemicals names, ranked by our analysis score (DSE has no market-cap feed). Descriptive comparison only.

ScripScorePriceUpsideYield

IBNSINAThe IBN SINA Pharmaceutical Industry PLC 87 ৳326.5 +12.00% +2.00%MARICOMarico Bangladesh Limited 87 ৳2,732.4 +24.00% +2.20%SQURPHARMASquare Pharmaceuticals PLC. 85 ৳221.4 +120.00% +5.40%ACMELABThe ACME Laboratories Limited 79 ৳86.9 +138.00% +4.10%BXPHARMABeximco Pharmaceuticals PLC. 78 ৳153.2 +54.00% +2.60%RENATARenata PLC 64 ৳464.3 -25.00% +1.20%

Historical outlook

Based on how similar setups behaved historically — not a prediction of what will happen.

10-day 40% vs 40% market avg Typical move: -5% / -1.2% / 3.6%

30-day 50% vs 42% market avg Typical move: -8.7% / -1.7% / 6.7%

Signals: Bearish Engulfing

Reference levels

Descriptive reference points from the analysis — not instructions to buy or sell.

Entry readSLEEVE only ≈15.6 (or dip 14.2)

Reference stopclose<14.2 (raw, tight)

Reference target⅓ at 18.4, trail rest

Timing notesleeve; enter Nov-Jan; OUT by Jun/Sep

Elevated (score 132) — acceptable only with real earnings and sponsor backing; artificial-activity lens applies. Phase: MID-MARKUP (43% >200-MA, flow ACC). HIGH sharp-fall risk 19% (top-decile). ⚠ SOLVENCY DISTRESS (Altman Z 18.91, RECOVERING) — bankruptcy risk. high-risk. [fundamentals AT-RISK (dividend cut risk), yield 0.6%]